

November 22, 2021

Mark Litton, Ph.D.
Chief Executive Officer
Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Re: Athira Pharma, Inc.
Registration

Statement on Form S-3
2021

Filed November 15,

File No. 333-261073

Dear Dr. Litton:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact
Christine Westbrook at 202-551-5019 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Bryan King, Esq.